Novavax Inc (NVAX)
$3.95
0.00 (0.00%)
NVAX Stock Quote Delayed 30 Minutes
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
294.21M
PE Ratio
-0.71
EPS
-5.56
Volume (Avg. Vol.)
21,788
Day's Range
-
52-Week Range
$3.53 - $11.36
Dividend & Yield
N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax Inc News
Why Is Novavax (NVAX) Stock in the Spotlight Today?
Novavax (NVAX) stock is on the move Wednesday following positive data from its Phase 3 PREVENT-19 vaccine trial and Study 307.
5 Investors Betting Big on Novavax (NVAX) Stock
NVAX stock is in focus as the company receives a recommendation from the Swiss health agency concerning its Nuvaxovid drug.
Novavax (NVAX) Stock Pops 8% With Vaccine Talks Underway
Today, investors in Novavax and NVAX stock are cheering the start of a major conference on vaccine tech, which Novavax is a part of.
Dear NVAX Stock Fans, Mark Your Calendars for Oct. 11
Shares of NVAX stock are climbing ahead of the World Vaccine Congress Europe 2022, where Novavax will share new vaccine data.
A Shot of NVAX Stock Is NOT What Your Portfolio Needs
Even before Biden's 'pandemic is over' declaration, NVAX stock struggled due to weak demand for Novavax's Covid-19 shots.
Why Is Novavax (NVAX) Stock Falling Today?
Novavax still has cash, but it needs to get approval for another vaccine if NVAX stock is to be worth buying again.
Why Are Vaccine Stocks MRNA, PFE, NVAX, BNTX Down Today?
Vaccine stocks are taking it on the chin following President Biden's comments that the "pandemic is over." What now?
Why Is Novavax (NVAX) Stock Down Today?
Pfizer and Moderna received FDA approval for their omicron-specific booster. NVAX stock is hitting new 52-week lows in response.
Why Is Novavax (NVAX) Stock Plunging 30%?
Shares of NVAX stock are falling after the company cut its revenue outlook in half and delivered a poor Q2 earnings report.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off Tuesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on today!
The CDC Just Gave Novavax (NVAX) Stock a Big Boost
Novavax stock is up 6% today after the U.S. Centers for Disease Control and Prevention (CDC) approved its two-dose Covid-19 vaccine for use in adults.
2 Big Reasons Novavax (NVAX) Stock Is Shooting Higher Today
Novavax has several catalysts igniting NVAX stock higher today. The bulls hope this is just the beginning for NVAX shares.
Is Novavax (NVAX) Stock a Buy After FDA Decision?
Novavax (NVAX) stock is in the spotlight on Friday as investors react to recent FDA news concerning its Covid-19 vaccine.
What Is Going on With Novavax (NVAX) Stock Today?
NVAX stock is falling on news that European regulators have placed a new warning on the company's Covid-19 vaccine.
Novavax (NVAX) Stock Pops Ahead of FDA Approval
NVAX stock has risen nearly 10% in the past five trading sessions on expectations that the FDA is going to approve its Covid-19 vaccine.
More Vaccine Jabs Means Novavax Stock Is Up for Grabs
NVAX stock looks due for a bounce-back as Novavax makes strides in providing Covid-19 vaccines in the U.S. and internationally.
What Is Going on With Novavax (NVAX) Stock Today?
NVAX stock is down more than 8% today even after a surprise announcement of a vaccine deal with the U.S. government.
